Voyager Therapeutics, Inc. (VYGR): Price and Financial Metrics


Voyager Therapeutics, Inc. (VYGR): $5.91

-0.03 (-0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VYGR POWR Grades


  • Growth is the dimension where VYGR ranks best; there it ranks ahead of 97.88% of US stocks.
  • The strongest trend for VYGR is in Value, which has been heading down over the past 179 days.
  • VYGR's current lowest rank is in the Stability metric (where it is better than 5.4% of US stocks).

VYGR Stock Summary

  • The ratio of debt to operating expenses for Voyager Therapeutics Inc is higher than it is for about merely 0.5% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Voyager Therapeutics Inc is reporting a growth rate of -292.72%; that's higher than merely 6.57% of US stocks.
  • As for revenue growth, note that VYGR's revenue has grown -78.14% over the past 12 months; that beats the revenue growth of only 1.44% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Voyager Therapeutics Inc are CRIS, AGLE, SURF, CHRS, and FUSN.
  • Visit VYGR's SEC page to see the company's official filings. To visit the company's web site, go to www.voyagertherapeutics.com.

VYGR Valuation Summary

  • VYGR's EV/EBIT ratio is 0.3; this is 98.98% lower than that of the median Healthcare stock.
  • VYGR's price/earnings ratio has moved up 23.7 over the prior 71 months.
  • VYGR's price/earnings ratio has moved up 23.7 over the prior 71 months.

Below are key valuation metrics over time for VYGR.

Stock Date P/S P/B P/E EV/EBIT
VYGR 2021-08-31 0.9 1.1 6.9 0.3
VYGR 2021-08-30 0.9 1.1 6.8 0.2
VYGR 2021-08-27 0.9 1.1 6.5 -0.1
VYGR 2021-08-26 0.9 1.1 6.7 0.1
VYGR 2021-08-25 0.9 1.1 6.9 0.3
VYGR 2021-08-24 0.9 1.1 6.8 0.2

VYGR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VYGR has a Quality Grade of D, ranking ahead of 16.57% of graded US stocks.
  • VYGR's asset turnover comes in at 0.071 -- ranking 290th of 681 Pharmaceutical Products stocks.
  • JAGX, SGEN, and OTLC are the stocks whose asset turnover ratios are most correlated with VYGR.

The table below shows VYGR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.071 1 -1.098
2021-06-30 0.541 1 0.193
2021-03-31 0.598 1 0.402
2020-12-31 0.595 1 0.386
2020-09-30 0.634 1 0.362
2020-06-30 0.296 1 -0.420

VYGR Price Target

For more insight on analysts targets of VYGR, see our VYGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.06 Average Broker Recommendation 1.78 (Moderate Buy)

VYGR Stock Price Chart Interactive Chart >

Price chart for VYGR

VYGR Price/Volume Stats

Current price $5.91 52-week high $10.60
Prev. close $5.94 52-week low $2.46
Day low $5.63 Volume 338,769
Day high $6.06 Avg. volume 603,903
50-day MA $6.28 Dividend yield N/A
200-day MA $4.74 Market Cap 227.27M

Voyager Therapeutics, Inc. (VYGR) Company Bio


Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company was founded in 2013 and is based in Cambridge, Massachusetts.


VYGR Latest News Stream


Event/Time News Detail
Loading, please wait...

VYGR Latest Social Stream


Loading social stream, please wait...

View Full VYGR Social Stream

Latest VYGR News From Around the Web

Below are the latest news stories about Voyager Therapeutics Inc that investors may wish to consider to help them evaluate VYGR as an investment opportunity.

We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 22, 2022

Will Voyager Therapeutics (VYGR) Report Negative Q4 Earnings? What You Should Know

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor conferences. SVB Leerink 11th Annual Global Healthcare Conference, company presentation, Feb. 18, 2022, 9:20 a.m. ETCowen 42nd Annual Health Care Conference, corporate panel discussion, Mar. 9, 2022, 12:50 p.m

Yahoo | February 10, 2022

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics'' Board of Directors and Newly Formed Executive Committee

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors, effective February 7, and a newly formed Executive Committee of the Board consisting of Dr. Sandrock, Michael Higgins, interim chief executive officer and Board Chairman, and Glenn Pierce, M.D., Ph.D., interim chief scientific officer and Board member. Dr. Sandrock will work with Voyager leadership to help shape futur...

Benzinga | February 3, 2022

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee

Al Sandrock Al Sandrock, Executive Committee Member at Voyager Therapeutics TRACER Capsid Discovery Platform TRACER Capsid Discovery Platform Michael Higgins Michael Higgins, Interim Chief Executive Officer of Voyager Therapeutics Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therap

Yahoo | February 3, 2022

Read More 'VYGR' Stories Here

VYGR Price Returns

1-mo -2.48%
3-mo -29.05%
6-mo 118.08%
1-year 43.10%
3-year -78.83%
5-year -34.04%
YTD 118.08%
2021 -62.10%
2020 -48.75%
2019 48.40%
2018 -43.37%
2017 30.30%

Continue Researching VYGR

Here are a few links from around the web to help you further your research on Voyager Therapeutics Inc's stock as an investment opportunity:

Voyager Therapeutics Inc (VYGR) Stock Price | Nasdaq
Voyager Therapeutics Inc (VYGR) Stock Quote, History and News - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5967 seconds.